The major goals for professor David Communi are to decipher molecular mechanisms implicated in cellular signalling, as well as to discover novel clinical biomarkers, by using structural and quantitative proteomics (and metabolomics) for various neurological or systemic pathologies, such as multiple sclerosis, acute brain injury, encephalitis and idiopathic pulmonary fibrosis. It represents a mandatory step to improve precision medicine for diagnosis, prognosis and therapeutic follow-up. Moreover, the discovery of novel biomarkers will also provide new insights in the understanding of the molecular mechanisms of diseases.
- To Handle robustly, with high uptime, complex biological samples for fundamental and clinical research
- Identify and quantify with confidence, thousands of proteins (and their post-translational modifications) or metabolites
- Translate the mass spectrometry approach from biomarker detection to clinical routine assays
- A complete strategy including efficient biochemical sample process, reproducible SWATH® Acquisition mass spectrometry analysis, as well as bio-informatical tools for the identification and the quantification of thousands of biomolecules.
- Generation of reproducible data from large-scale studies and retrospective data mining
- Detection of novel partners and post-translational modifications of key molecules implicated in cellular signalling
- Discovery of novel biomarker panels in clinical fluids and tissues for a better understanding and monitoring of human pathologies